PER-120-07
Completed
未知
Immunogenicity Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Comparison to Infanrix®Hexa, at 2-4-6 Months of Age in Healthy Peruvian Infants
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- -Z278 Need for immunisation against other combinations of infectious diseases
- Sponsor
- SANOFI PASTEUR S.A.,
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Infants two months of age (OS at 71 days of age) on the day of inclusion, of both sexes.
- •Born at term (\> 37 weeks) and with a birth weight\> 2\.5 kg.
- •Negative mother for hepatitis B surface antigen (HBsAg) in the last trimester of pregnancy (from\> 29 weeks of amenorrhea) or in the 4 weeks after delivery.
- •Informed consent form signed by both parents. If one or both parents are under 18 years of age, the subject´s grandparents must also sign. You must also sign an independent witness if the parents / grandparents are illiterate.
- •Ability to attend all scheduled visits and complete all study procedures.
- •Have received the BCG vaccine between birth and month of life, according to the national immunization schedule.
Exclusion Criteria
- •Participation in another clinical study in the 4 weeks prior to the first vaccination of the study.
- •Planned participation in another clinical study during the period of this study.
- •Known systemic hypersensitivity to any component of the vaccine, or a history of life\-threatening reactions by administration of the study vaccine or a vaccine containing the same substances.
- •Congenital or acquired immunodeficiency, or immunosuppressive therapies such as therapy with long\-term systemic corticosteroids (more than 2 weeks) in the last four weeks
- •Chronic disease in a stage that could interfere with the completion or completion of the study.
- •Administration of blood or blood products from birth.
- •Any vaccination applied in the 4 weeks prior to the first vaccination of the study.
- •Any planned vaccination during the study (up to V06\), except for study vaccines, rotavirus vaccine and conjugated pneumococcal vaccines.
- •Documented history of infections due to pertussis, tetanus, diphtheria, poliomyelitis, hepatitis B or Haemophilus influenzae type b (clinically, serologically or microbiologically confirmed).
- •Prevaccination against pertussis, tetanus, diphtheria, polio, hepatitis B or Haemophilus influenzae type b infections.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study to Assess the Immune Response and the Safety Profile of DTaP-IPVHB- PRP~T Combined Vaccine Given Concomitantly or Sequentially with 4CMenB Vaccine in Italian InfantsHaemophilus influenzae type b immunisationMedDRA version: 21.1Level: LLTClassification code 10054181Term: Hepatitis B immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10069533Term: Haemophilus influenzae type b immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2019-002585-12-ITSANOFI PASTEUR396
Active, not recruiting
Phase 1
Study to Assess the Immune Response and the Safety Profile of DTaP-IPV-HB-PRP~T Combined Vaccine Given Concomitantly or Sequentially with 4CMenB Vaccine in Italian and Finnish InfantsHaemophilus influenzae type b immunisationMedDRA version: 21.1Level: LLTClassification code 10054181Term: Hepatitis B immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10069533Term: Haemophilus influenzae type b immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2019-002585-12-FISanofi Pasteur200
Completed
Phase 2
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean InfantsDiphtheriaTetanusPertussisHaemophilus Influenzae Type bPoliomyelitisNCT00831311Sanofi Pasteur, a Sanofi Company624
Completed
Phase 3
Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months ScheduleHepatitis BPolioDiphtheriaPertussisNCT00315055Sanofi Pasteur, a Sanofi Company310
Completed
Phase 3
Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio VaccineDiphtheriaTetanusPertussisHepatitis BHaemophilus InfectionsNCT00343889Sanofi Pasteur, a Sanofi Company379